Core Laboratories (NYSE:CLB) Updates Q2 2026 Earnings Guidance

Core Laboratories (NYSE:CLB) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.060-0.120 for the period, compared to the consensus earnings per share estimate of 0.150. The company issued revenue guidance of $123.0 million-$131.0 million, compared to the consensus revenue estimate of $127.8 million.

Core Laboratories Stock Down 15.2%

NYSE:CLB traded down $2.64 during midday trading on Thursday, reaching $14.67. 1,630,695 shares of the stock traded hands, compared to its average volume of 308,800. Core Laboratories has a 12-month low of $9.72 and a 12-month high of $20.36. The business has a 50-day moving average of $16.66 and a two-hundred day moving average of $16.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.51 and a current ratio of 2.02. The stock has a market capitalization of $675.32 million, a PE ratio of 22.56, a price-to-earnings-growth ratio of 3.25 and a beta of 1.15.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, April 29th. The oil and gas company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. Core Laboratories had a net margin of 5.94% and a return on equity of 11.55%. The company had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $122.99 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. Core Laboratories’s revenue for the quarter was down 1.4% compared to the same quarter last year. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS. On average, equities analysts forecast that Core Laboratories will post 0.57 earnings per share for the current fiscal year.

Core Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Monday, May 11th will be paid a $0.01 dividend. The ex-dividend date is Monday, May 11th. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. Core Laboratories’s dividend payout ratio (DPR) is 5.97%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Core Laboratories in a report on Friday, March 27th. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Core Laboratories presently has a consensus rating of “Hold” and an average price target of $12.50.

Core Laboratories News Summary

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Board approved a small quarterly dividend ($0.01/share; ex-dividend May 11, payable June 1), providing modest income support and signaling confidence in cash returns. Read More.
• Positive Sentiment: Company repurchased ~51,781 shares for about $0.9M in the quarter — a modest buyback that slightly offsets dilution and shows some capital return activity. Read More.
• Neutral Sentiment: Q1 results: GAAP EPS of $0.06 matched consensus and revenue was $121.8M (roughly flat YoY, slightly off some estimates). Operating income is low and EPS ex-items declined vs prior periods. Investors have mixed reads: in-line earnings but weakening underlying metrics. Read More.
• Neutral Sentiment: Management hosted an earnings call; the transcript discusses operational disruptions and margin drivers — useful for investors wanting color on whether issues are transitory or structural. Read More.
• Negative Sentiment: Q2 guidance was lowered: EPS guidance $0.060–0.120 vs. analyst consensus ~ $0.150, and revenue guidance $123M–$131M below some Street forecasts — the guidance miss is the primary reason for the negative reaction. Read More.
• Negative Sentiment: Margins and operations were hit by geopolitical uncertainty and weather-related disruptions, which the company cites as drivers of weaker profitability — a risk to near-term margin recovery. Read More.
• Negative Sentiment: Cash flow and balance-sheet trends are concerning: free cash flow was minimal (~$0.5M), net debt increased ~$3.9M and leverage is ~1.20 — these raise questions about capital flexibility if results don’t improve. Read More.

Hedge Funds Weigh In On Core Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Core Laboratories by 6.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after acquiring an additional 1,040 shares during the last quarter. iSAM Funds UK Ltd purchased a new stake in shares of Core Laboratories in the 3rd quarter valued at $202,000. Quantbot Technologies LP boosted its holdings in shares of Core Laboratories by 343.7% in the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock valued at $202,000 after acquiring an additional 13,571 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Core Laboratories by 49.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,132 shares of the oil and gas company’s stock valued at $199,000 after acquiring an additional 5,345 shares during the last quarter. Finally, Quantessence Capital LLC purchased a new stake in shares of Core Laboratories in the 3rd quarter valued at $192,000. Hedge funds and other institutional investors own 97.81% of the company’s stock.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.